Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY ™ (Romosozumab) In Postmenopausal Women With Osteoporosis

ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures Imbalance in Cardiovascular Events Observed as New Safety Signal THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint. At the primary analysis, treatment with EVENITY for 12 months followed by alendronate significantly reduced the incidence of new vertebral fractures through 24 months, clinical fractures (primary endpoints) and non-vertebral fractures (key secondary endpoint)...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news